Irvin Epstein

1.3k total citations
18 papers, 983 citations indexed

About

Irvin Epstein is a scholar working on Psychiatry and Mental health, Pharmacology and Clinical Psychology. According to data from OpenAlex, Irvin Epstein has authored 18 papers receiving a total of 983 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 6 papers in Pharmacology and 6 papers in Clinical Psychology. Recurrent topics in Irvin Epstein's work include Schizophrenia research and treatment (9 papers), Treatment of Major Depression (6 papers) and Obsessive-Compulsive Spectrum Disorders (4 papers). Irvin Epstein is often cited by papers focused on Schizophrenia research and treatment (9 papers), Treatment of Major Depression (6 papers) and Obsessive-Compulsive Spectrum Disorders (4 papers). Irvin Epstein collaborates with scholars based in Canada, United States and Australia. Irvin Epstein's co-authors include Robert B. Zipursky, Jean Addington, Alan Breier, Thomas H. McGlashan, Adrian Preda, Tandy J. Miller, Keith A. Hawkins, Mauricio Tohen, Scott W. Woods and Diana O. Perkins and has published in prestigious journals such as American Journal of Psychiatry, Psychiatry Research and Schizophrenia Research.

In The Last Decade

Irvin Epstein

15 papers receiving 955 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Irvin Epstein Canada 12 796 385 317 189 138 18 983
Barbara C. Walsh United States 12 1.0k 1.3× 407 1.1× 416 1.3× 183 1.0× 202 1.5× 18 1.3k
Nikolai Albert Denmark 16 844 1.1× 352 0.9× 308 1.0× 131 0.7× 195 1.4× 40 1.0k
Denise Gretchen‐Doorly United States 12 860 1.1× 310 0.8× 260 0.8× 227 1.2× 108 0.8× 17 1.0k
Marco Cappucciati Italy 14 951 1.2× 427 1.1× 337 1.1× 245 1.3× 297 2.2× 21 1.2k
J.P. Lindenmayer United States 11 820 1.0× 189 0.5× 319 1.0× 224 1.2× 91 0.7× 17 1.1k
Alison Blair United Kingdom 5 658 0.8× 352 0.9× 275 0.9× 105 0.6× 103 0.7× 10 810
Berna Binnur Akdede Türkiye 17 788 1.0× 178 0.5× 318 1.0× 196 1.0× 98 0.7× 58 1.1k
Gabriele Nibbio Italy 18 716 0.9× 246 0.6× 336 1.1× 224 1.2× 129 0.9× 52 1.0k
Danijela Piškulić Canada 17 825 1.0× 250 0.6× 304 1.0× 293 1.6× 94 0.7× 29 1.2k
Stephen M. Erhart United States 8 802 1.0× 191 0.5× 232 0.7× 184 1.0× 87 0.6× 8 1.0k

Countries citing papers authored by Irvin Epstein

Since Specialization
Citations

This map shows the geographic impact of Irvin Epstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irvin Epstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irvin Epstein more than expected).

Fields of papers citing papers by Irvin Epstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irvin Epstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irvin Epstein. The network helps show where Irvin Epstein may publish in the future.

Co-authorship network of co-authors of Irvin Epstein

This figure shows the co-authorship network connecting the top 25 collaborators of Irvin Epstein. A scholar is included among the top collaborators of Irvin Epstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irvin Epstein. Irvin Epstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
3.
4.
Epstein, Irvin, et al.. (2018). Low hedonic tone and attention-deficit hyperactivity disorder: risk factors for treatment resistance in depressed adults. Neuropsychiatric Disease and Treatment. Volume 14. 2379–2387. 17 indexed citations
5.
Nasiri, Khadijeh, et al.. (2018). Examining predictors of help-seeking behaviours in patients with mood and anxiety symptoms. Psychiatry Research. 265. 190–197. 10 indexed citations
6.
Aucoin, Monique, Kieran Cooley, Melissa Furtado, et al.. (2017). Adjunctive Vitamin D in the treatment of non-remitted depression: Lessons from a failed clinical trial. Complementary Therapies in Medicine. 36. 38–45. 13 indexed citations
7.
Counsell, Alyssa, et al.. (2017). Intolerance of uncertainty, social anxiety, and generalized anxiety: Differences by diagnosis and symptoms. Psychiatry Research. 252. 63–69. 51 indexed citations
8.
Epstein, Irvin, et al.. (2014). Pharmacological approaches to manage persistent symptoms of major depressive disorder: rationale and therapeutic strategies. Psychiatry Research. 220. S15–S33. 15 indexed citations
9.
Marshall, Catherine, Jean Addington, Irvin Epstein, et al.. (2011). Treating young individuals at clinical high risk for psychosis. Early Intervention in Psychiatry. 6(1). 60–68. 24 indexed citations
10.
Addington, Jean, Irvin Epstein, Lu Liu, et al.. (2010). A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research. 125(1). 54–61. 169 indexed citations
11.
Addington, Jean, et al.. (2008). Early detection of psychosis: finding those at clinical high risk. Early Intervention in Psychiatry. 2(3). 147–153. 32 indexed citations
12.
Simon, Andor E., Helen Lester, Lynda Tait, et al.. (2008). The International Study on General Practitioners and Early Psychosis (IGPS). Schizophrenia Research. 108(1-3). 182–190. 34 indexed citations
13.
McGlashan, Thomas H., Robert B. Zipursky, Diana O. Perkins, et al.. (2006). Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal of Psychiatry. 163(5). 790–799. 403 indexed citations
14.
Epstein, Irvin, et al.. (2006). An overview of the genetic risk of developing schizophrenia in relatives of schizophrenic patients.. PubMed. 11(1). 7–10. 1 indexed citations
15.
Zipursky, Robert B., Bruce K. Christensen, Zafiris J. Daskalakis, et al.. (2005). Treatment Response to Olanzapine and Haloperidol and its Association with Dopamine D2 Receptor Occupancy in First-Episode Psychosis. The Canadian Journal of Psychiatry. 50(8). 462–469. 25 indexed citations
16.
Miller, Tandy J., Robert B. Zipursky, Diana O. Perkins, et al.. (2003). The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. Schizophrenia Research. 61(1). 19–30. 120 indexed citations
17.
Tauscher‐Wisniewski, Sitra, Shitij Kapur, J. Tauscher, et al.. (2002). Quetiapine: An Effective Antipsychotic in First-Episode Schizophrenia Despite Only Transiently High Dopamine-2 Receptor Blockade. The Journal of Clinical Psychiatry. 63(11). 992–997. 68 indexed citations
18.
Epstein, Irvin, et al.. (1986). [Intestinal microflora in patients with myocardial infarct].. PubMed. 44–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara C. Walsh Breakdown of academic impact, for papers by Nikolai Albert Breakdown of academic impact, for papers by Denise Gretchen‐Doorly Breakdown of academic impact, for papers by Marco Cappucciati Breakdown of academic impact, for papers by J.P. Lindenmayer Breakdown of academic impact, for papers by Alison Blair Breakdown of academic impact, for papers by Berna Binnur Akdede Breakdown of academic impact, for papers by Gabriele Nibbio Breakdown of academic impact, for papers by Danijela Piškulić Breakdown of academic impact, for papers by Stephen M. Erhart
Rankless by CCL
2026